ReviewInternational journal of clinical oncology2026
Head and neck cancer of unknown primary: a nationwide analysis of hospital-based cancer registry data in Japan, 2018-2022.
Review in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSome head and neck cancers are metastatic tumors of unknown primary origin, but their epidemiology has seldom been studied. This study aimed to address this knowledge gap using a nationwide database in Japan. Furthermore, we examined the nationwide implementation of human papillomavirus (HPV) and Epstein-Barr virus (EBV) testing, assessed their inter-facility and temporal variations, and compared these findings with oropharyngeal cancer cases.
methodsHead and neck squamous cell carcinoma of unknown primary origin and oropharyngeal squamous cell carcinoma diagnosed between 2018 and 2022 were identified from the Hospital-based Cancer Registries of Japan. Data on sex, age, TNM classification, HPV and EBV test results, and treatment facilities were collected. Temporal changes in viral diagnostic practices were analyzed.
resultsWe identified 1636 new cases of head and neck cancers of unknown primary. The disease was more common in males and patients aged 70-74 years. HPV positivity was more frequent in patients aged 45-59 years, whereas EBV positivity was less frequent in all age groups. Of the patients, 67.6% were treated at certified head and neck cancer facilities, which had higher viral testing rates than non-certified facilities. Case numbers remained stable over time, whereas viral testing and HPV positivity increased; however, both remained lower than in oropharyngeal cancer cases.
conclusionsThis study visualized real-world virus testing for patients with head and neck cancers of unknown primary, providing insights into diagnostic equity, institutional capacity, and the need for standardized cancer care. Continued surveillance is essential to improve outcomes in this rare condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.